专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010039668A2 INHIBITORS OF CYCLIN KINASE INHIBITOR P21 审中-公开
标题翻译：细胞周期蛋白激酶抑制剂P21的抑制剂
公开(公告)号：WO2010039668A2
公开(公告)日：2010-04-08
申请号：PCT/US2009058697
申请日：2009-09-29
申请人： UNIV CALIFORNIA , WEISS ROBERT , PARK SEE-HYOUNG , LAM KIT S , LIU RUIWU
发明人： WEISS ROBERT , PARK SEE-HYOUNG , LAM KIT S , LIU RUIWU
IPC分类号： C07D403/06 , A61K31/4184 , A61P35/00 , C07D235/06 , C07D403/04
CPC分类号： C07D401/04 , C07D235/18 , C07D401/06 , C07D401/14 , C07D403/12 , C07D405/14 , C07D455/02
摘要： The present invention provides compounds that inhibit cyclin kinase inhibitor p21, such as compounds of formula I. The present invention also provides compositions including compounds of Formula I and a pharmaceutically acceptable excipient. In addition, the present invention provides methods of inhibiting cyclin kinase inhibitor p21 and of treating cancer.
摘要翻译：本发明提供了抑制细胞周期蛋白激酶抑制剂p21的化合物，例如式I化合物。本发明还提供了包含式I化合物和药学上可接受的赋形剂的组合物。此外，本发明提供了抑制细胞周期蛋白激酶抑制剂p21和治疗癌症的方法。

2. 发明申请

WO2008031016A3 HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY 审中-公开
标题翻译：用于整合成像和治疗的异位配体
公开(公告)号：WO2008031016A3
公开(公告)日：2008-11-27
申请号：PCT/US2007077860
申请日：2007-09-07
申请人： UNIV CALIFORNIA , CARPENTER RICHARD D , ANDREI MIRELA , LIU RUIWU , LAM KIT S , KURTH MARK J
发明人： CARPENTER RICHARD D , ANDREI MIRELA , LIU RUIWU , LAM KIT S , KURTH MARK J
IPC分类号： A61K31/33
CPC分类号： A61K51/0459 , A61K9/0014 , A61K9/0019 , A61K51/0453 , A61K51/0455
摘要： The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
摘要翻译：本发明提供显示高结合亲和力，特异性和稳定性的4β1整联蛋白配体。配体包含具有n个独立选择的氨基酸的肽，其中至少一个氨基酸是非天然氨基酸或D-氨基酸，并且其中n是3-20的整数。提供了用于给予治疗癌症，炎性疾病和自身免疫性疾病。还提供了施用用于成像受试者的肿瘤，器官或组织的配体的方法。

3. 发明申请

WO2008036449A9 CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING 审中-公开
标题翻译：用于免疫治疗和成像的化学抗体
公开(公告)号：WO2008036449A9
公开(公告)日：2009-02-12
申请号：PCT/US2007072400
申请日：2007-06-28
申请人： UNIV CALIFORNIA , LAM KIT S , KUMARESAN PAPPANAICKEN R , ENSTROM AMANDA , LIU RUIWU
发明人： LAM KIT S , KUMARESAN PAPPANAICKEN R , ENSTROM AMANDA , LIU RUIWU
IPC分类号： A61K51/00
CPC分类号： A61K47/6835 , A61K47/62 , A61K47/646
摘要： The present invention provides antibody conjugates comprising a targeting agent covalently attached to an antibody or fragment thereof. The antibody conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, infectious diseases, and neurological disorders. Kits containing the antibody conjugates described herein find utility in a wide range of applications including, for example, in vivo imaging and immunotherapy.
摘要翻译：本发明提供了包含与抗体或其片段共价连接的靶向剂的抗体偶联物。本发明的抗体缀合物对于肿瘤，器官或组织的成像以及用于治疗诸如癌症，炎性疾病，自身免疫疾病，感染性疾病和神经疾病的疾病和病症特别有用。含有本文所述抗体缀合物的试剂盒可用于广泛的应用，包括例如体内成像和免疫疗法。

4. 发明申请

WO2008036449A2 CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING 审中-公开
标题翻译：用于免疫和成像的化学抗体
公开(公告)号：WO2008036449A2
公开(公告)日：2008-03-27
申请号：PCT/US2007072400
申请日：2007-06-28
申请人： UNIV CALIFORNIA , LAM KIT S , KUMARESAN PAPPANAICKEN R , ENSTROM AMANDA , LIU RUIWU
发明人： LAM KIT S , KUMARESAN PAPPANAICKEN R , ENSTROM AMANDA , LIU RUIWU
IPC分类号： A61K51/00
CPC分类号： A61K47/6835 , A61K47/62 , A61K47/646
摘要： The present invention provides antibody conjugates comprising a targeting agent covalently attached to an antibody or fragment thereof. The antibody conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, infectious diseases, and neurological disorders. Kits containing the antibody conjugates described herein find utility in a wide range of applications including, for example, in vivo imaging and immunotherapy.
摘要翻译：本发明提供了包含与抗体或其片段共价连接的靶向试剂的抗体缀合物。本发明的抗体缀合物特别可用于成像肿瘤，器官或组织并用于治疗诸如癌症，炎性疾病，自身免疫疾病，感染性疾病和神经障碍的疾病和病症。含有本文所述的抗体缀合物的试剂盒可用于广泛的应用，包括例如体内成像和免疫治疗。

5. 发明申请

WO2012031228A2 LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT 审中-公开
标题翻译：用于骨质疏松症治疗的LLP2A-二磷酸盐结合物
公开(公告)号：WO2012031228A2
公开(公告)日：2012-03-08
申请号：PCT/US2011050381
申请日：2011-09-02
申请人： UNIV CALIFORNIA , LAM KIT S , LIU RUIWU , YAO WEI , LANE NANCY
发明人： LAM KIT S , LIU RUIWU , YAO WEI , LANE NANCY
IPC分类号： C07K7/08 , A61K38/10 , A61P19/08 , C07K7/06
CPC分类号： C07K5/0821 , A61K31/00 , A61K31/66 , A61K31/661 , A61K31/663 , A61K35/28 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/10 , A61K47/48084 , A61K47/48246 , A61K47/548 , A61K47/64 , C07F9/02 , C07K5/0817 , C07K5/101 , C07K5/1016 , C07K5/1019 , C07K7/06
摘要： The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the a4ß1 integrin on mesenchymal stem cells and for the surface of bone.
摘要翻译：本发明提供了肽模拟配体的化合物和药物组合物，例如与双膦酸盐药物缀合的LLP2A，例如阿仑膦酸钠。本发明的化合物和药物组合物可用于治疗骨质疏松症和促进骨生长，因为它们对间质干细胞和骨表面上的α4β1整联蛋白的特异性。

6. 发明申请

WO2005122379A9 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY 审中-公开
标题翻译：用于成像和治疗的ALPHA-4 BETA-1 INTEGRIN配体
公开(公告)号：WO2005122379A9
公开(公告)日：2006-03-09
申请号：PCT/US2005018730
申请日：2005-05-26
申请人： UNIV CALIFORNIA , LAM KIT S , LIU RUIWU , PENG LI
发明人： LAM KIT S , LIU RUIWU , PENG LI
IPC分类号： A61K45/06 , C07C275/42 , C07K5/02 , C07K7/02 , H02N1/00
CPC分类号： C07C275/42 , A61K38/00 , A61K45/06 , B82Y5/00 , B82Y10/00 , B82Y30/00 , C07K5/021 , C07K5/0815 , C07K5/1019 , C07K7/02
摘要： The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
摘要翻译：本发明提供显示高结合亲和力，特异性和稳定性的4β1整联蛋白配体。配体包含具有n个独立选择的氨基酸的肽，其中至少一个氨基酸是非天然氨基酸或D-氨基酸，并且其中n是3-20的整数。提供了用于给予治疗癌症，炎性疾病和自身免疫性疾病。还提供了施用用于成像受试者的肿瘤，器官或组织的配体的方法。

7. 发明申请

WO2005122379A2 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY 审中-公开
标题翻译：用于成像和治疗的ALPHA-4 BETA-1整合配体
公开(公告)号：WO2005122379A2
公开(公告)日：2005-12-22
申请号：PCT/US2005018730
申请日：2005-05-26
申请人： UNIV CALIFORNIA , LAM KIT S , LIU RUIWU , PENG LI
发明人： LAM KIT S , LIU RUIWU , PENG LI
IPC分类号： A61K45/06 , C07C275/42 , C07K5/02 , C07K7/02 , H02N1/00
CPC分类号： C07C275/42 , A61K38/00 , A61K45/06 , B82Y5/00 , B82Y10/00 , B82Y30/00 , C07K5/021 , C07K5/0815 , C07K5/1019 , C07K7/02
摘要： The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
摘要翻译：本发明提供显示高结合亲和力，特异性和稳定性的4β1整联蛋白配体。配体包含具有n个独立选择的氨基酸的肽，其中至少一个氨基酸是非天然氨基酸或D-氨基酸，并且其中n是3-20的整数。提供了用于给予治疗癌症，炎性疾病和自身免疫性疾病。还提供了施用用于成像受试者的肿瘤，器官或组织的配体的方法。

8. 发明申请

WO2010039496A2 NANOCARRIERS FOR DRUG DELIVERY 审中-公开
标题翻译：纳米级用于药物递送
公开(公告)号：WO2010039496A2
公开(公告)日：2010-04-08
申请号：PCT/US2009057852
申请日：2009-09-22
申请人： UNIV CALIFORNIA , LAM KIT S , LUO JUNTAO
发明人： LAM KIT S , LUO JUNTAO
IPC分类号： A61K9/127 , A61K9/51 , A61K47/10 , A61K47/14 , A61K47/48
CPC分类号： A61K49/0002 , A61K9/1075 , A61K9/5146 , A61K47/48215 , A61K47/488 , A61K47/60 , A61K47/6907 , A61K49/0032 , A61K49/0082 , B82Y5/00
摘要： The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.
摘要翻译：本发明提供具有内部和外部的纳米载体，纳米载体包含至少一种缀合物，其中每种缀合物包含聚乙二醇（PEG）聚合物。每种缀合物还包含至少两种具有亲水面和疏水面的两亲化合物。另外，每种缀合物都包含寡聚物，其中至少两种两亲化合物共价连接至与PEG共价连接的寡聚物。纳米载体使得每种缀合物在含水溶剂中自组装以形成纳米载体，使得疏水口袋通过每种两亲化合物的疏水面朝向彼此的方向在纳米载体的内部形成，并且其中PEG 每个缀合物自组装在纳米载体的外部。

9. 发明申请

WO2012158622A2 REVERSIBLY CROSSLINKED MICELLE SYSTEMS 审中-公开
标题翻译：可反复交流的MICELLE系统
公开(公告)号：WO2012158622A2
公开(公告)日：2012-11-22
申请号：PCT/US2012037794
申请日：2012-05-14
申请人： UNIV CALIFORNIA , LAM KIT S , LI YUANPEI , LUO JUNTAO , XIAO KAI
发明人： LAM KIT S , LI YUANPEI , LUO JUNTAO , XIAO KAI
CPC分类号： C08G65/3348 , A61K9/1075 , A61K9/1271 , A61K31/337 , A61K45/06 , A61K47/28 , A61K47/60 , C08G65/329 , C08G83/004 , C08L71/02 , Y10T428/2982
摘要： The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
摘要翻译：本发明提供了聚合形成以疏水核心和亲水外部为特征的纳米载体的两亲性的前体衍生物。纳米载体核可以包括两亲官能团，例如胆酸或胆酸衍生物，并且外部可以包括支链或直链的聚（乙二醇）链段。纳米载体如疏水性药物和其他材料可以通过非共价方式螯合在核心中，或者可以共价结合到四聚体上。 Teendendrimer结构可以被定制以改变负载特性，与诸如生物膜的材料的相互作用以及其它特征。

10. 发明申请

WO2010148346A3 THREE-DIMENSIONAL CELL ADHESION MATRIX 审中-公开
标题翻译：三维细胞粘附基质
公开(公告)号：WO2010148346A3
公开(公告)日：2011-04-21
申请号：PCT/US2010039241
申请日：2010-06-18
申请人： UNIV CALIFORNIA , ONOFIOK EKAMA , LAM KIT S , LUO JUNTAO
发明人： ONOFIOK EKAMA , LAM KIT S , LUO JUNTAO
IPC分类号： C09J129/04 , C08L29/04 , C12N11/08
CPC分类号： C09J129/04 , C08K5/55 , C12N5/0062 , C12N2533/30
摘要： The present invention provides a cell adhesion matrix having poly(vinyl alcohol) chains crosslinked via carboxy phenyl boronic acid crosslinkers. The cell adhesion matrix can also include a molecular recognition element bound to the poly(vinyl alcohol) chains via a carboxy phenyl boronic acid group, as well as including cells. The present invention also provides a method for making and de-gelling the cell adhesion matrix.
摘要翻译：本发明提供具有通过羧基苯基硼酸交联剂交联的聚（乙烯醇）链的细胞粘附基质。细胞粘附基质还可以包括通过羧基苯基硼酸基与聚（乙烯醇）链结合的分子识别元件，以及包括细胞。本发明还提供了一种使细胞粘附基质制造和去胶凝的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式